2025–2026 Radiology Imaging AI & MedTech Report

In 2025, these four segments did not move in lockstep. Radiology practices and imaging centers benefited from strong procedure demand, especially in advanced imaging, but still faced reimbursement pressure and labor shortages. Imaging AI attracted premium interest where the product had FDA clearance, workflow integration, recurring revenue, and proof of ROI. Medical device manufacturing remained one of the more durable healthcare-adjacent M&A categories, with better pricing for differentiated, regulated, high-margin manufacturers than for generic job-shop style producers. Heading into 2026, the broad setup looks constructive: demand is solid, strategic buyers remain active, and medtech deal value rebounded sharply in 2025, but buyers are still selective and pay premiums mainly for scale, technology, margin durability, and clean regulatory posture.